Symphogen, a Copenhagen, Denmark-based biopharmaceutical company developing recombinant antibody mixtures, closed an additional €41m financing.
Backers included Novo A/S and PKA with investments of €20 million each, and Danica Pension. In conjunction with the financing, Dr. Anthony Tolcher, President and Co-Founder of START, joined Symphogen’s Board.
The company intends to use the funds to advance and expand its proprietary oncology product pipeline of antibody mixture products.
Led by Kirsten Drejer, PhD., Chief Executive Officer, Symphogen is developing antibody therapeutics for the treatment of cancer. The company has currently brought two product candidates into the clinic. The lead oncology product, Sym004, was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.
In total, Symphogen has raised € 249m in equity capital from investors including Novo, Essex Woodlands Health Ventures and PKA.
It employs 90 people.
FinSMEs
03/05/2013
Related News
06/01/2011: Symphogen Closes €100M Round of Financing
02/04/2012: Symphogen Receives Second Tranche of €100m Financing